125472-02-8
Chemical Structure
Mivazerol
- CAS No.: 125472-02-8
- Formula:C11H11N3O2
- Molecular Weight:217.22
IUPAC Name: 3-((1H-imidazol-5-yl)methyl)-2-hydroxybenzamide
InChIKey: RLHGFJMGWQXPBW-UHFFFAOYSA-N
SMILES: O=C(C1=CC=CC(CC2=CN=CN2)=C1O)N
Biological Activity: Mivazerol is a selective α2-adrenoceptor agonist. Mivazerol decreases the spontaneous release of serotonin (5-HT) and significantly inhibits the immobilization stress-induced enhancement of norepinephrine (NE), dopamine (DA) and dihydroxyphenylacetic acid (DOPAC). Mivazerol inhibits intrathecal release of glutamate evoked by halothane withdrawal in rats, and exerts neuroprotective effects in forebrain ischemia rats. Mivazerol can be used for myocardial ischemia research[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Mivazerol | Mivazerol is a selective α2-adrenoceptor agonist. Mivazerol decreases the spontaneous release of serotonin (5-HT) and significantly inhibits the immobilization stress-induced enhancement of norepinephrine (NE), dopamine (DA) and dihydroxyphenylacetic acid (DOPAC). Mivazerol inhibits intrathecal release of glutamate evoked by halothane withdrawal in rats, and exerts neuroprotective effects in forebrain ischemia rats. Mivazerol can be used for myocardial ischemia research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Zhang X, et al. Mivazerol inhibits intrathecal release of glutamate evoked by halothane withdrawal in rats. Acta Anaesthesiol Scand. 1998;42(8):1004-1009. [Content Brief]
- [2]. Kimura T, et al. Neuroprotective effect of mivazerol, an alpha 2-agonist, after transient forebrain ischemia in rats. Acta Anaesthesiol Scand. 2005 Sep;49(8):1117-23. [Content Brief]
- [3]. Kimura T, et al. Effect of mivazerol, a alpha-agonist, on striatal norepinephrine concentration during transient forebrain ischemia in rats. Acta Anaesthesiol Scand. 2008 Aug;52(7):997-1002. [Content Brief]
Keywords
